Integrated BioPharma Valuation
Is INBP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of INBP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate INBP's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate INBP's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INBP?
Key metric: As INBP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is INBP's PE Ratio? | |
|---|---|
| PE Ratio | 23.7x |
| Earnings | US$430.00k |
| Market Cap | US$10.23m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.2x |
| Enterprise Value/EBITDA | 8.5x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does INBP's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.5x | ||
UG United-Guardian | 12.8x | n/a | US$46.0m |
SNYR Synergy CHC | 9.9x | n/a | US$51.4m |
NHTC Natural Health Trends | 83.4x | n/a | US$61.6m |
AXIL AXIL Brands | 7.9x | n/a | US$24.2m |
INBP Integrated BioPharma | 23.7x | n/a | US$10.2m |
Price-To-Earnings vs Peers: INBP is good value based on its Price-To-Earnings Ratio (23.7x) compared to the peer average (28.5x).
Price to Earnings Ratio vs Industry
How does INBP's PE Ratio compare vs other companies in the US Personal Products Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
NEPT.F Neptune Wellness Solutions | n/a | n/a | US$4.00 |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: INBP is good value based on its Price-To-Earnings Ratio (23.7x) compared to the North American Personal Products industry average (26.6x).
Price to Earnings Ratio vs Fair Ratio
What is INBP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 23.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate INBP's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Kimberly-Clark
US$45.2b
Manufactures and markets personal care and consumer tissue products in the United States.
KMB
US$136.37
7D
3.2%
1Y
11.5%
Beauty Health
US$200.5m
Designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide.
SKIN
US$1.49
7D
-19.5%
1Y
-33.0%
Kimberly-Clark de México S. A. B. de C. V
Mex$86.7b
Manufactures, distributes, and sells disposable products in Mexico.
KCDM.F
Mex$1.37
7D
-5.8%
1Y
n/a